Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Trending topics among doctors today!
Trending topics among doctors today!
As few as about 2,600 and about 2,800 steps/day yielded significant mortality and cardiovascular disease benefits, in a study published in the Journal of the American College of Cardiology. Progressive risk reductions were observed up to an optimal 7,200 steps/day…
In the Phase IIIb HARMONIE trial, nirsevimab (Beyfortus) drastically reduced infant respiratory syncitial virus (RSV) hospitalisations by 83%, and reduced all-cause lower respiratory tract infection hospitalisations by 58% (n = 8058). RSV is the most common cause of respiratory tract…
In the Phase III INSPIRES trial, clopidogrel-aspirin led to a lower risk of new stroke at 90 days than aspirin alone (7.3% vs. 9.2%, p = 0.008), in patients with mild ischemic stroke or high-risk transient ischemic attack of presumed…
The FDA has issued an update to the ciltacabtagene autoleucel (CARVYKTI) label describing secondary AML/MDS in 10% of patients treated on CARTITUDE-1 (10/97). CARTITUDE-1 is a Phase IB/II trial that evaluated ciltacabtagene autoleucel (CARVYKTI) in patients with relapsed of refractory…
In a cross-sectional study of 2775 patients with colorectal cancer from 2011 to 2016, decreased use of neoadjuvant radiotherapy (87% to 37%) was not associated with changes in 4-year local recurrence (5.8% vs 5.5%) in patients with lower risk rectal…
A new structural class of antibiotics has been discovered using deep learning-guided exploration of chemical spaces. The last one took 38 years! The article published in Nature identified compounds with efficacy against multiple bacteria (without toxicity), including methicillin-resistant Staphylococcus aureus…
177Lu-PNT2002 met its primary endpoint of radiographic progression-free survival (rPFS) in the pivotal Phase III SPLASH trial (9.5 months vs 6.0 months, HR 0.71), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor…